Andrew Schutte, a Director, acquired 1,125,500 Common Shares on a direct ownership basis at a price of $0.180 through a prospectus or prospectus exempt offering on July 15th, 2020. The insider also acquired 562,750 Warrants on a direct ownership basis at an exercise price of $0.360 until July 23, 2023. This represents a $202,590 investment into the company's shares and an account share holdings change of 59.5%.
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions.
No Comments